The senior management consists of the Chief Executive Officer, Chief Operating Officer, Chief Financial Officer, Chief Scientific Officer, Chief Medical Officer, Director of Corporate Affairs and Head of Human Resources.

CEO Sofia Heigis, Oncopeptides AB

Sofia Heigis, MSc

Chief Executive Officer, CEO

Sofia was appointed Chief Executive Officer in August 2023.

Sofia joined Oncopeptides in August 2020 as Senior Vice President and Global Head Medical Affairs. She was appointed Chief Commercial Officer and Managing Director Germany in 2022. Sofia was engaged in the preparedness and launch of Pepaxto in the US, and has led the preparations of the commercialization of Pepaxti in Europe. She has been a member of the Leadership Team since November 2021.

Sofia brings broad experience from leading international roles in Medical Affairs, Regulatory Affairs, Market Ethics, Pharmacovigilance, Real World Evidence as well as several Marketing and Sales roles at Astra Zeneca, and has been engaged in both global and local product launches.

Sofia holds a Master of Pharmacology from the University of Gothenburg, including a Master Thesis in Pharmacology from Bond University. She has an Executive Master in Strategy, and is a member of the business network for female leaders, Ruter Dam.

Born: 1980

Holdings in Oncopeptides: 86,908 shares, 1,776,502 share awards* and 123,561 options*.

Other current positions: –

Portrait of Eva Nordström

Eva Nordström, MSc Pharm

Chief Operating Officer (COO) and Deputy Managing Director

Eva Nordström was appointed as Head of Clinical Development in 2012, Chief Operating Officer 2020 and Deputy Managing Director 2021. Eva is responsible for strategic and operational deliveries in Biometrics, CMC, Clinical Operations, Global Drug Supply and Preclinical Operations.

Previous positions Eva has held include Global Product Director and Vice President roles at Pharmacia and AstraZeneca based both in Sweden and the USA. She has led international cross-functional teams through all phases of drug development, including phase III and product launches. Eva has been responsible for individual project strategies including their implementation as well as disease area strategies, portfolio management and in-licensing.

Eva holds an MSc Pharm from Uppsala University and an Executive MBA from Stockholm School of Economics.

Born: 1970

Holdings in Oncopeptides: 280,464 shares, 316,295 share awards* and 363,665 options*.

Other current positions: Board member of Oxcia AB, Alternate Director of Utilica AB.

Henrik Bergentoft - CFO Oncopeptides AB

Henrik Bergentoft, MSc

Chief Financial Officer (CFO)

Henrik was appointed CFO in 2023 and is responsible for Finance, Legal, IT and administration.

Henrik brings broad experience from  several CFO-positions in listed companies; RaySearch Laboratories, C-RAD, MSAB, Nordkom, Aerocrine and Contextvision. He started his career as auditor with Andersen/Deloitte.

Education: Henrik has a Master of science in Business Administration from the University of Uppsala.

Born: 1974

Holdings in Oncopeptides: 23,332 shares and 79,728 share awards*.

Other current positions: –

Portrait of David Augustsson

David Augustsson

Director of IR and Communications

David Augustsson joined Oncopeptides in 2023 as Head of the company’s investor relations, communications and corporate brand.

David has a broad experience from leading communication roles in international and listed companies. Between 2016 and 2023, he worked for global financial services company Nasdaq, where he led the communications teams for the company’s European operations as well as its global technology business. He has also worked as a consultant at a number of agencies, including Prime WeberShandwick and Hill+Knowlton, where he primarily has worked with financial communications and issues management. David is also a regular guest lecturer within strategic communication and issues management at Berghs School of Communication in Stockholm.

David holds a Master’s degree in International Economics and Management from Uppsala University and Wirtschaftsuniversität Vienna

Born: 1984

Holdings in Oncopeptides: 16,332 shares and 60,483 share awards*

Other current positions: –

Sara Svärdgren, Head of HR at Oncopeptides AB

Sara Svärdgren

Head of Human Resources

Sara joined Oncopeptides in May 2018 as Head of Human Resources. Since May 2022, she is a member of the company’s leadership team.

Sara has a broad experience of HR and has held managerial positions in HR during the past 10 years. Before joining Oncopeptides, she worked in the financial industry at Neonet Securities AB.

Sara has studied the Human Resources program with a major in psychology at Örebro University and Stockholm University.

Born: 1979

Holdings in Oncopeptides: 85 shares, 46,689 share awards* and 12,158 options*.

Other current positions: –

Stefan Norin, Chief Medical Officer at Oncopeptides AB

Stefan Norin, MD, PhD

Chief Medical Officer (CMO)

Stefan was appointed as Chief Medical Officer in September 2023.

Stefan joined Oncopeptides in March 2019, as Clinical Study Physician, appointed Global Clinical Lead in 2020, Head of Clinical Development in 2022 and Head of Clinical Science in 2023.

In his role, he is responsible for Research & Development and Pharmacovigilance.

Stefan has a background as a specialist in Internal Medicine and Hematology and has 20 years of clinical experience. He has a PhD from Karolinska Institute.

Previous roles include Associate Director, Clinical R&D at Medivir AB and Head of Lymphoma Division, Department of Hematology at Karolinska University Hospital.

Born: 1972

Holdings in Oncopeptides: 9,664 shares, 126,456 share awards* and 14,957 options*.

Other current positions: 


Portrait of Jakob Lindberg

Jakob Lindberg, Med Lic

Senior Scientific Advisor to the Leadership Team

Jakob Lindberg was the CEO of Oncopeptides from 2011 until June 2020, as well as from November 2021 until January 2023. During July 2020 until November 2021 and between January 2023 and May 2024 he was the Chief Scientific Officer of Oncopeptides. Previous roles include being an analyst at Merrill Lynch & Co and a consultant at McKinsey & Co. Jakob was co-founder of Cellectricon, a provider of cell-based screening services to accelerate drug discovery, where he has also served as CEO.

Jakob has studied medicine at the Karolinska Institute. He gained a Med Lic in Molecular Immunology and a MSc in pre-clinical medicine. He also has a BA in Finance and Administration from the Stockholm University.

* The options and share awards entitles to 1,28 shares per option/share award in accordance with existing terms.

For more information and terms please read under Corporate Governance – Remuneration.

Holdings in Oncopeptides AB (publ) as of June 20, 2024.